MSB

0.51%

97.0¢ mesoblast limited

things I've learnt over the last 14 months, page-7

First 7 Last

Share
Profile

Follow
AlbertE

4,553 Posts.

693

17/05/17

11:55

Post #: 24740199
Share

Originally posted by DerekT ↑

I've just old my final mesoblast shares in the last few weeks, having only held for around 14 months. Have made a 35% profit in that time, and I'm glad I'm out. Here's why:

1) There is something very unprofessional about the corporate updates and other communication this company provides. I'm not sure if it reflect dodginess or incompetence, but I'm not comfortable with them having my money
2) this company essentially has 1 product. They then package and brand this single product under multiple names and have somehow convinced some people that they have cures to multiple previously incurable diseases. Does this seem likely? Also, the TGA has just spoken its mind on the re-packaging of a single drug for multiple individual diseases (Ibuprofen).
3) Stem cells were supposed to be used to grow new tissue (e.g. for damaged hearts, damaged spinal cords). This hasn't happened. And it looks to me like stem cell companies are having to find uses for their very expensive products by testing them against every incurable disease out there. I am a doctor (in an unrelated field), but I did attend a half-day session on stem cells last year at a North American conference, and all the researchers there thought that clinical applications are at least a decade away. Of note and relevance to mesoblast, they used the GVHD product as an example of a failed drug (and failed company), and a paediatric cardiac surgeon from Boston presented on using stem cells for congenital heart disease and basically just present a series of negative studies. He was not optimistic. I don't think MSB is going to be curing any previously incurable diseases anytime soon.
4) As seen on this message board, people are either believers or non-believers, and tend to have very strong feelings either way. This doesn't happen for companies whose science is solid (e.g. CSL).
5) Financing and capital raising - the way this companies deals with investment banks and stock brokers is amateur, even by Australian standard. They have been taken for a ride, and there is no reason to think it won't happen again.

If I was interested in trading, I can see how it is possible to make money out of this company. I generally hold for the long term, and this company is not for me.

I'll continue to follow with interest. Good luck.

Expand

Why the lengthy exposition. Who cares why you sold and are glad you are out? It appears you are risk averse and this company is not for you.

Good luck being out. Meanwhile this drop in price which has prompted you to sell, has provided myself an opportunity to buy more at lower prices.

This company has the potential (so far progress has been positive) to change the face of healthcare/medicine moving into the future. And for the betterment of us all. Is it without risk - Obviously not, we are not naive - but a worthy cause I am willing to put my hard earned on.

MSB Price at posting: $2.33 Sentiment: Buy Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

The Rising Tide: How institutional adoption is shaping the future of crypto

NRX

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

RDN

Raiden gears up for exploration in final quarter of 2024

Reporting wrap: Inghams, Accent, Mayne Pharma

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

EXR

HotCopper users humming as Elixir Energy reports first gas flowed to surface at Daydream-2, QLD; shares jump 15%

IPH

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

The business of sport: Warren Tredrea's take on this week's news

There are more pages in this discussion • 19 more messages in this thread...

First 7 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 97.0¢		Change -0.005(0.51%)		Mkt cap ! $1.107B

Open	High	Low	Value	Volume
98.5¢	98.5¢	96.0¢	$2.168M	2.226M

Buyers (Bids)

No.	Vol.	Price($)
1	16000	96.5¢

Sellers (Offers)

Price($)	Vol.	No.
97.0¢	86854	7

View Market Depth

No.	Vol.	Price($)
1	16000	0.965
1	23000	0.960
8	163220	0.955
8	87646	0.950
3	82684	0.945

Price($)	Vol.	No.
0.970	86854	7
0.975	37184	2
0.980	44810	6
0.985	88504	4
0.990	54328	5

Last trade - 16.10pm 23/08/2024 (20 minute delay)

MSB (ASX) Chart

things I've learnt over the last 14 months, page-7

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

The Rising Tide: How institutional adoption is shaping the future of crypto

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

Raiden gears up for exploration in final quarter of 2024

Reporting wrap: Inghams, Accent, Mayne Pharma

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

HotCopper users humming as Elixir Energy reports first gas flowed to surface at Daydream-2, QLD; shares jump 15%

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

The business of sport: Warren Tredrea's take on this week's news

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

things I've learnt over the last 14 months, page-7

Top Stories

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

The Rising Tide: How institutional adoption is shaping the future of crypto

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

Raiden gears up for exploration in final quarter of 2024

Reporting wrap: Inghams, Accent, Mayne Pharma

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

HotCopper users humming as Elixir Energy reports first gas flowed to surface at Daydream-2, QLD; shares jump 15%

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

The business of sport: Warren Tredrea's take on this week's news

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News